The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited
Abstract
OBJECTIVE— The Diabetes Control and Complications Trial (Diabetes 44:968–983, 1995) presented statistical models suggesting that subjects with similar A1C levels had a higher risk of retinopathy progression in the conventional treatment group than in the intensive treatment group. That analysis has been cited to support the hypothesis that specific patterns of glucose variation, in particular postprandial hyperglycemia, contribute uniquely to an increased risk of microvascular complications above and beyond that explained by the A1C level. RESEARCH DESIGN AND METHODS— We performed statistical evaluations of these models and additional analyses to assess whether the original analyses were flawed. RESULTS— Statistically, we show that the original results are an artifact of the assumptions of the statistical model used. Additional analyses show that virtually all (96%) of the beneficial effect of intensive versus conventional therapy on progression of retinopathy is explained by the reductions in the mean A1C levels, similarly for other outcomes. Furthermore, subjects within the intensive and conventional treatment groups with similar A1C levels over time have similar risks of retinopathy progression, especially after adjusting for factors in which they differ. CONCLUSIONS— A1C explains virtually all of the difference in risk of complications between the intensive and conventional groups, and a given A1C level has similar effects within the two treatment groups. While other components of hyperglycemia, such as glucose variation, may contribute to the risk of complications, such factors can only explain a small part of the differences in risk between intensive and conventional therapy over time.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.-P., & Colette, C. (2006) · JAMA · doi:10.1001/jama.295.14.1681 · Cited by 2,444
The Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Fundus Photographic Risk Factors for Progression of Diabetic Retinopathy
(1991) · Ophthalmology · doi:10.1016/s0161-6420(13)38014-2 · Cited by 814
Diabetes Control and Complications Trial (DCCT) Research Group (1996) · Diabetes · doi:10.2337/diab.45.10.1289 · Cited by 597
Glycemic Variability: A Hemoglobin A1c–Independent Risk Factor for Diabetic Complications
Brownlee, M., & Hirsch, I. B. (2006) · JAMA · doi:10.1001/jama.295.14.1707 · Cited by 482
The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2006) · Diabetes Care · doi:10.2337/dc06-0293 · Cited by 377
Biostatistical methods : the assessment of relative risks
Lachin, J. M. (2000) · Cited by 272
Self-citation
Cited by
Items 201–300 of 555
Type 2 Diabetes Mellitus: Managing Hemoglobin A1c and Beyond
Fowler, G. C., & Vasudevan, D. A. (2010) · Southern Medical Journal · doi:10.1097/smj.0b013e3181eb34b2 · Cited by 25
“Among other conflicting results, an epidemiological reanalysis of the large DCCT outcomes trial failed to show the original results of an independent, consistent effect of glucose fluctuations—in particular, PPG—on microvascular complications.(23) Although glucose variation may contribute to the risk of disease-relate…”
BackgroundResultInfluentialGlycemic Variability: Looking Beyond the A1C
Tylee, T. S., & Trence, D. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.3.149 · Cited by 28
Lee, M., Hsiao, P., Huang, Y.-T., Huang, J., Hsu, W., Chen, S., & Shin, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178319 · Cited by 25
Diabetes and Vascular Disease: Is It All About Glycemia?
Vecchié, A., Montecucco, F., Carbone, F., Dallegri, F., & Bonaventura, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190830181944 · Cited by 24
Hepatic non-parenchymal S100A9-TLR4-mTORC1 axis normalizes diabetic ketogenesis
Ursino, G., Ramadori, G., Höfler, A., Odouard, S., Teixeira, P. D. S., Visentin, F., Veyrat‐Durebex, C., Lucibello, G., Firnkes, R., Ricci, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31803-5 · Cited by 24
Diabetic macular oedema: clinical risk factors and emerging genetic influences
Liu, E., Craig, J. E., & Burdon, K. P. (2017) · Clinical and Experimental Optometry · doi:10.1111/cxo.12552 · Cited by 23
Cardiovascular Risk Factors: It's Time to Focus on Variability!
Barnett, M. P., & Bangalore, S. (2020) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2020.9.2.255 · Cited by 25
Relationship between daily and visit-to-visit glycemic variability in patients with type 2 diabetes
Tsuchiya, T., Saisho, Y., Murakami, R., Watanabe, Y., Inaishi, J., & Itoh, H. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0012 · Cited by 23
“However, the correlation between GV and the development of diabetic complications has been reported inconsistently in patients with diabetes [20, 21].”
BackgroundKrämer, A. L., Riederer, A., Fracassi, F., Boretti, F. S., Sieber‐Ruckstuhl, N. S., Lutz, T. A., Contiero, B., Zini, E., & Reusch, C. E. (2020) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15915 · Cited by 27
Kalavar, M., Al-khersan, H., Sridhar, J. S., Gorniak, R., Lakhani, P. C., Flanders, A. E., & Kuriyan, A. E. (2020) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000333 · Cited by 24
Blot, G., Karadayi, R., Przegralek, L., Sartoris, T.-M., Charles‐Messance, H., Augustin, S., Négrier, P., Blond, F., Muñiz-Ruvalcaba, F. P., la Parra, D. R.-D., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci161348 · Cited by 29
“DR is a multifactorial disease, and hyperglycemia only accounts for a limited proportion of the risk of developing DR (15).”
BackgroundStudy of factors associated with poor glycemic control in Type -2 Diabetic patients
Prabhakara, K., Jayarama, N., Sri Sai Prasad, M., & Gopinath, B. (2013) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 22
The role of mass spectrometry in studies of glycation processes and diabetes management
DaRonco, S., Crotti, S., Agostini, M., Traldi, P., Chilelli, N. C., & Lapolla, A. (2018) · Mass Spectrometry Reviews · doi:10.1002/mas.21576 · Cited by 22
Optimal treatment of diabetic retinopathy
Hammes, H. (2013) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018813477886 · Cited by 24
Abcouwer, S. F. (2012) · Diabetes · doi:10.2337/db12-1223 · Cited by 23
“Until recently, intensive glycemic control, with its risks of hypoglycemic events and increased mortality, was the only known means of reducing the progression of diabetic retinopathy (2,3).”
BackgroundIs It Time to Replace Time-in-Range with Time-in-Tight-Range? Maybe Not
Beck, R. W. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0602 · Cited by 23
“11,12 In data from the Swedish registry, the risks of retinopathy and microalbuminuria for HbA1c < 6.5% were similar to the risks with HbA1c 6.5%–6.9% and didn’t increase substantially until HbA1c was > 8.6% 13 ; death rates in Based on the dataset described in Ref.”
InfluentialMellor, J., Jeyam, A., Beulens, J. W. J., Bhandari, S., Broadhead, G., Chew, E. Y., Fickweiler, W., van der Heijden, A. A. W. A., Gordin, D., Simó, R., et al. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100494 · Cited by 25
“61 Plasma glucose variability is an important reason accounting for the weaknesses of the HbA1c level in predicting the development and progression of DRD.”
Layered Meta-Learning Algorithm for Predicting Adverse Events in Type 1 Diabetes
D’Antoni, F., Petrosino, L., Marchetti, A., Bacco, L., Pieralice, S., Vollero, L., Pozzilli, P., Piemonte, V., & Merone, M. (2023) · IEEE Access · doi:10.1109/access.2023.3237992 · Cited by 22
Continuous Glucose Monitoring in Dogs and Cats
Baldo, F. D., & Fracassi, F. (2023) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2023.01.008 · Cited by 23
Mehta, S. N., Schwartz, N., Wood, J., Svoren, B. M., & Laffel, L. M. (2011) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2011.00830.x · Cited by 20
Diabetes Research and Care Through the Ages
Zinman, B., Skyler, J. S., Riddle, M. C., & Ferrannini, E. (2017) · Diabetes Care · doi:10.2337/dci17-0042 · Cited by 23
Self-citationRobles‐Osorio, L., García-Franco, R., Núñez‐Amaro, C. D., Mira, X., Ramírez-Neria, P., Hernández, W., López-Star, E. M., Bertsch, T., de la Escalera, G. M., Triebel, J., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00242 · Cited by 20
100 most-cited articles on diabetic retinopathy
Koh, B. M. Q. R., Banu, R., Nusinovici, S., & Sabanayagam, C. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316609 · Cited by 24
Fisher, E., Lazar, L., Shalitin, S., Yackobovitch‐Gavan, M., de Vries, L., Oron, T., Tenenbaum, A., Phillip, M., & Lebenthal, Y. (2018) · Journal of Diabetes Research · doi:10.1155/2018/9572817 · Cited by 21
“The Diabetes Control and Complications Trial (DCCT), based on a regimen of monthly clinic visits with a multidisciplinary team, clearly demonstrated the positive impact of intensive diabetes therapy on glycemic control [1].”
MethodAlışık, M., & Işık, M. U. (2020) · Current Eye Research · doi:10.1080/02713683.2020.1842463 · Cited by 19
Identifying Genetic Risk Factors for Diabetic Macular Edema and the Response to Treatment
Gurung, R. L., FitzGerald, L. M., McComish, B. J., Verma, N., & Burdon, K. P. (2020) · Journal of Diabetes Research · doi:10.1155/2020/5016916 · Cited by 19
Lachin, J. M., Bebu, I., Gao, X., Nathan, D. M., & Zinman, B. (2022) · Diabetes Care · doi:10.2337/dc21-2298 · Cited by 19
Self-citationFirouzabadi, F. D., Poopak, A., Samimi, S., Deravi, N., Nakhaei, P., Sheikhy, A., Moosaie, F., Rabizadeh, S., Meysamie, A., Nakhjavani, M., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1383345 · Cited by 23
Point: Intensive Glycemic Control and Mortality in ACCORD—A Chance Finding?
Lachin, J. M. (2010) · Diabetes Care · doi:10.2337/dc10-1506 · Cited by 19
“An example was provided by the DCCT (10).”
MethodSelf-citationSilvares, R. R., Pereira, E. N. G. D. S., Flores, E. E. I., Estato, V., Reis, P. A., da Silva, I. J., Pelajo‐Machado, M., Neto, H. C. D. C. F., Tibiriçá, E. V., & Daliry, A. (2016) · International Journal of Experimental Pathology · doi:10.1111/iep.12184 · Cited by 21
Chantelau, E. A., Meyer-Schwickerath, R., & Klabe, K. (2009) · Ophthalmologica · doi:10.1159/000260231 · Cited by 19
“EW has to be discerned from the chronic late worsening (LW) of diabetic retinopathy, which has traditionally been viewed as the typical natural course of diabetic retinopathy. According to this view, LW develops gradually as a consequence of the cumulative glycemic load the retina is exposed to over years. However, th…”
BackgroundViklund, G., & Wikblad, K. F. (2010) · Acta Paediatrica · doi:10.1111/j.1651-2227.2009.01615.x · Cited by 19
“HbA1c was measured using high-performance liquid chromatography, either as blood collected on filter paper (values were converted to the Mono-S method using the formula (Mono-S = DCCT (15) standard x 1.0678–1.341) or the DCA2000 (Siemens, gives Mono-S values).”
MethodInfluentialCryer, P. E., & Arbeláez, A. M. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch35 · Cited by 26
车松天, Ma, Y., Fu, J., Zhou, X., & Cao, J. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.150272 · Cited by 23
HbA1c Variability as an Independent Risk Factor for Microvascular Complications in Type 1 Diabetes
Mao, Y., & Zhong, W. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221100833 · Cited by 20
Staimez, L. R., Kipling, L. M., Ham, J. N., Legvold, B. T., Jackson, S. L., Wilson, P. W. F., Rhee, M. K., & Phillips, L. S. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109935 · Cited by 22
Liu, H., Zhang, W., Hu, Q., Liu, L., Xie, Z., Xu, Y., Jing, G., & Wang, Y. (2022) · International Wound Journal · doi:10.1111/iwj.13948 · Cited by 20
Diabetes mellitus associated neurovascular lesions in the retina and brain: A review
Sinclair, S. H., Miller, E. S., Talekar, K. S., & Schwartz, S. S. (2022) · Frontiers in Ophthalmology · doi:10.3389/fopht.2022.1012804 · Cited by 21
Zong, G.-W., Wang, W.-Y., Zheng, J., Zhang, W., Luo, W.-M., Fang, Z., & Zhang, Q. (2023) · Journal of Diabetes Research · doi:10.1155/2023/3990035 · Cited by 18
“under good glycemic control in patients [23, 24].”
Hirsch, I. B., Amiel, S. A., Blumer, I. R., Bode, B. W., Edelman, S. V., Seley, J. J., Verderese, C. A., & Kilpatrick, E. S. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0132 · Cited by 18
“19,20 The pitfall of extrapolating from such population-based assessments of glycemic control when advising individuals ‘‘in the exam room’’ is exemplified by a recent chart review in which 9% of 600 consecutive patients had conditions that would preclude the use of A1C.”
Ambulatory glucose profile (AGP): utility in UK clinical practice
Evans, M. L., CRANSTON, I. C., & Bailey, C. J. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.121 · Cited by 19
Estimating HbA1c from timed Self-Monitored Blood Glucose values
Fan, W., Zheng, H., Wei, N., & Nathan, D. M. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.023 · Cited by 19
Self-citationRole of Inflammation in Diabetic Retinopathy
Sharma, A., & Arora, D. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100175 · Cited by 18
Zhang, Y., Jenkins, A. J., Basu, A., Stoner, J. A., Lopes-Virella, M. F., Klein, R. L., & Lyons, T. J. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p060657 · Cited by 18
Glycaemic control, glucose variability and the Triangle of Diabetes Care
Rayman, G. A. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.070 · Cited by 18
Successes and Disappointments with Clinical Islet Transplantation
Cravedi, P., van der Meer, I. M., Cattaneo, S. G. D. A., Ruggenenti, P. L., & Remuzzi, G. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_33 · Cited by 20
“In 1993, the Diabetes Control and Complications Trial (DCCT) showed that a system of intensive diabetes management aimed at near-normal glycemic control dramatically reduces the risk of microvascular complications and favorably affects the risk of macrovascular complications compared to a less strict control approach…”
BackgroundBiomarkers of diabetic retinopathy
Cunha-Vaz, J. G., Ribeiro, L., Nunes, S. G., & Lobo, C. L. (2014) · Diabetes Management · doi:10.2217/dmt.13.67 · Cited by 16
Takenouchi, A., Tsuboi, A., Terazawa-Watanabe, M., Kurata, M., Fukuo, K., & Kazumi, T. (2015) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-015-0201-y · Cited by 22
“Long-term glycemic control, as expressed by hemoglobin (Hb) A1c levels, is the main risk factor for the development of microvascular complications including diabetic kidney disease [2, 3].”
BackgroundDesign Considerations for Artificial Pancreas Pivotal Studies
Russell, S. J., & Beck, R. W. (2015) · Diabetes Care · doi:10.2337/dc15-2449 · Cited by 18
“the reduction in complications associated with further lowering of HbA1c below 7% (53 mmol/mol) is low in absolute terms (12,13) and consistent control at a higher level of HbA1c may be sufficient to prevent microvascular complications (14).”
BackgroundLepore, G., Bruttomesso, D., Bonomo, M., Dodesini, A. R., Costa, S., Meneghini, E., Corsi, A. M., Nosari, I., & Trevisan, R. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02736.x · Cited by 17
Impact of Glucose Fluctuation on Acute Cerebral Infarction in Type 2 Diabetes
Huang, J., Zhang, X., Li, J., Tang, L., Jiao, X., & Lv, X. (2014) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100018539 · Cited by 17
Diabetes Technology: Monitoring, Analytics, and Optimal Control
Kovatchev, B. P. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034389 · Cited by 17
Akyüz, S., Bahçecioğlu, A. B., Güven, H. E., Başak, A. M., & Yılmaz, K. B. (2023) · Turkish Journal of Trauma and Emergency Surgery · doi:10.14744/tjtes.2023.08939 · Cited by 25
Boehm, B. O., Dreyer, M., Fritsche, A., Füchtenbusch, M., Gölz, S., & Martin, S. (2012) · Diabetologie und Stoffwechsel · doi:10.1055/s-0032-1325579 · Cited by 17
CaM Kinase II-δ Is Required for Diabetic Hyperglycemia and Retinopathy but Not Nephropathy
Chen, J., Fleming, T. H., Katz, S., Dewenter, M., Hofmann, K. P., Saadatmand, A., Kronlage, M., Werner, M. P., Pokrandt, B., Schreiter, F. C., et al. (2020) · Diabetes · doi:10.2337/db19-0659 · Cited by 18
“However, some patients with well-adjusted glycemic control still develop late diabetic complications whereas others with less adequate control do not (3).”
BackgroundKetoacidosis at diagnosis in childhood-onset diabetes and the risk of retinopathy 20years later
Salardi, S., Porta, M., Maltoni, G., Cerutti, F., Rovere, S., Iafusco, D., Tumini, S., Cauvin, V., Zucchini, S., Cadario, F., et al. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.10.009 · Cited by 17
“Our findings, summarized in Table 3, confirm that long disease duration, higher age at diagnosis [13,28,29] and lifetime metabolic control [23,30] play a significant role in the risk of micro-vascular complications, whereas, similar to previous reports [11,12], severity of metabolic derangement or C-peptide levels at…”
ResultRaman, R., Verma, A., Pal, S. S., Gupta, A., Vaitheeswaran, K., & Sharma, T. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.01.006 · Cited by 16
Complications of Diabetes Mellitus
Brownlee, M., Aiello, L. P., Cooper, M. E., Vinik, A. I., Nesto, R. W., & Boulton, A. J. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00033-x · Cited by 22
Optimal Insulin Treatment in Type 2 Diabetes
Roden, M. (2009) · New England Journal of Medicine · doi:10.1056/nejme0908706 · Cited by 19
Ding, X., Romano, F., Garg, I., Gan, J., Vingopoulos, F., Garcia, M., Overbey, K. M., Cui, Y., Zhu, Y., Bennett, C. F., et al. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.10.016 · Cited by 20
Minuto, N., Emmanuele, V., Vannati, M., Russo, C., Rebora, C., Panarello, S. M., Pistorio, A., Lorini, R., & d’Annunzio, G. (2012) · PubMed · doi:10.3275/8016 · Cited by 17
Davoudi, S., & Sobrin, L. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.243 · Cited by 15
“In the Diabetes Control and Complications Trial (DCCT), duration of diabetes and HbA1c explained only about 11% of the variation in the risk of retinopathy [8, 9].”
BackgroundTargeting prandial hyperglycemia: How important is it and how best to do this?
Monnier, L., & Colette, C. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0064-4 · Cited by 15
TREATMENT ADHERENCE IN ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS
Soares, J. P. G., & Dell’Aglio, D. D. (2017) · Psicologia Saúde & Doenças · doi:10.15309/17psd180204 · Cited by 15
Adjunctive Treatments for Type 1 Diabetes
Nathan, D. M. (2017) · New England Journal of Medicine · doi:10.1056/nejme1711296 · Cited by 15
Self-citationCardiovascular morbidity and mortality in diabetes mellitus: prediction and prognosis.
Astrup, A. S. (2011) · PubMed · Cited by 15
Neeland, I. J., & Patel, K. V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54835-9.00004-1 · Cited by 14
Relationship Between Acylcarnitine and the Risk of Retinopathy in Type 2 Diabetes Mellitus
Wang, W., Liu, X., Gao, X., Li, X., & Fang, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.834205 · Cited by 14
Noninvasive Retinal Markers in Diabetic Retinopathy: Advancing from Bench towards Bedside
Blindbæk, S. L., Torp, T. L., Lundberg, K., Soelberg, K. K., Vergmann, A. S., Poulsen, C. D., Frydkjær-Olsen, U., Broe, R., Rasmussen, M. L., Wied, J., et al. (2017) · Journal of Diabetes Research · doi:10.1155/2017/2562759 · Cited by 17
“Nevertheless, the study also revealed that the combined effect of diabetes duration and glycemic regulation was only able to explain 11% of the total variation in the risk of DR, which leaves 89% for other reasons and mechanisms [4].”
BackgroundEpidemiology of Ocular Functions and Diseases in Persons With Diabetes
Klein, R., & Klein, R. (2018) · Europe PMC (PubMed Central) · Cited by 30
Shi, R., Lu, Y., Liu, D., & Guo, Z. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01775-x · Cited by 13
Olvera‐Barrios, A., Owen, C. G., Anderson, J., Warwick, A., Chambers, R., Bolter, L., Wu, Y., Welikala, R. A., Fajtl, J., Barman, S. A., et al. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003683 · Cited by 13
Lixisenatide as add-on therapy to basal insulin
Evans, M., Butler, E. L., & Brown, D. X. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s45108 · Cited by 17
Diallo, A. M., Novella, J., Lukas, C., Souchon, P., Dramé, M., François, M., Decoudier, B., Barraud, S., Salmon-Musial, A. S., Ancelle, D., et al. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.05.011 · Cited by 17
Yamamoto‐Honda, R., Kitazato, H., Hashimoto, S., Takahashi, Y., Yoshida, Y., Hasegawa, C., Akanuma, Y., & Noda, M. (2008) · Endocrine Journal · doi:10.1507/endocrj.k08e-071 · Cited by 15
New Potential Adjuncts to Treatment of Children With Type 1 Diabetes Mellitus
Raman, V. S., & Heptulla, R. A. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181975ee4 · Cited by 13
Kaya, A., Kar, T., Aksoy, Y., Özalper, V., & Başbuğ, B. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.09.018 · Cited by 13
Johansen, M. D., Gjerløv, I., Christiansen, J. S., & Hejlesen, O. K. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600221 · Cited by 13
Inzucchi, S. E., & Majumdar, S. K. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.018 · Cited by 15
Defining the Importance of Daily Glycemic Control and Implications for Type 2 Diabetes Management
Bode, B. W. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2055 · Cited by 18
Preventing Diabetic Retinopathy Progression
Ferris, F. L., & Nathan, D. M. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.05.039 · Cited by 13
Self-citationRetinopathy During the First 5 Years of Type 1 Diabetes and Subsequent Risk of Advanced Retinopathy
Malone, J. I., Gao, X., Lorenzi, G. M., Raskin, P., White, N. H., Hainsworth, D. P., Das, A., Tamborlane, W. V., Wallia, A., Aiello, L. P., et al. (2022) · Diabetes Care · doi:10.2337/dc22-1711 · Cited by 12
Differential correlation between time in range and eGFR or albuminuria in type 2 diabetes
Jin, X., Yang, X., Xu, Y., Liang, J., Liu, C., Guo, Q., Wang, W., Feng, Z., Yuan, Y., Zhou, H., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01071-4 · Cited by 14
Zhang, L., Sun, X., & Tian, Q. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02241-0 · Cited by 12
“For example, in the DCCT cohort [10, 11], only 11% of the variation in the risk of retinopathy could be explained by overall glycemic exposure (HbA1c and duration of diabetes).”
Initiation of Continuous Glucose Monitoring and Mortality in Type 2 Diabetes
Reaven, P. D., Macwan, S. A., Newell, M., Arani, G., Norman, G. J., Miller, D. R., & Zhou, J. J. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0227 · Cited by 14
“As poor glycemic control increases the risk for developing other serious conditions such as diabetic ketoacidosis, 31 renal disease, 32,33 and CVD, 32,34 and worsens the outcomes of a broad range of conditions when they occur, such as myocardial infarctions, heart failure, and infections, 35 – 40…”
Hu, J., Hsu, H., Yuan, X., Lou, K., Hsue, C., Miller, J. D., Lu, J., Lee, Y., & Lou, Q. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01410-6 · Cited by 15
Predictors of poor glycemic control in type 2 diabetic patients in South Indian population
De, P., Banu, S., & Muthukumar, D. (2018) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20180295 · Cited by 12
Wu, D., Gong, C., Meng, X., & Yang, Q. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20131841 · Cited by 13
Reverter, J. L., Nadal, J., Ballester, J., Ramió‐Lluch, L., del Alamo, M. M. R., Fernández-Novell, J. M., Elizalde, J., Abengoechea, S., & Rodríguez-Gil, J. E. (2011) · Ophthalmic Research · doi:10.1159/000323812 · Cited by 12
Impact of Prandial Plus Basal vs Basal Insulin on Glycemic Variability in Type 2 Diabetic Patients
Hirsch, I. B., Yuan, H., Campaigne, B. N., & Tan, M. H. (2009) · Endocrine Practice · doi:10.4158/ep08308.orr · Cited by 12
Wang, Y., Lu, J., Ni, J., Wang, M., Shen, Y., Lu, W., Zhu, W., Bao, Y., & Zhou, J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3639 · Cited by 12
Analysis of Aqueous Interleukin-6 in Diabetic Retinopathy
Manda, A. R., Lee, L. H., Steinkerchner, M. S., Sheng, J., Veach, L., Gangaputra, S. S., & Kim, S. J. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.06.014 · Cited by 14
Hine, P., Senniappan, S., Sankar, V., & Amin, R. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03170.x · Cited by 11
Prolactin and vasoinhibin are endogenous players in diabetic retinopathy revisited
Triebel, J., Bertsch, T., & Clapp, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.994898 · Cited by 12
“Consistently, the total glycemic exposure (A1C and duration of diabetes) explained only 11% of the variation in risk in the Diabetes Control and Complications Trial (DCCT) cohort, where retinopathy progression was studied in conventional and intensive treatment groups (12).”
BackgroundHemoglobin A1C, Mean Glucose, and Persistence of Glycation Ratios in Insulin-Treated Diabetes
Argento, N. B., Nakamura, K., Sala, R. D., & Simpson, P. C. (2013) · Endocrine Practice · doi:10.4158/ep13079.or · Cited by 11
Landgraf, R., Kellerer, M., Aberle, J., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., et al. (2018) · Diabetologie und Stoffwechsel · doi:10.1055/a-0598-0475 · Cited by 18
Lockhart, C., McCann, A. J., Agnew, C. E., Hamilton, P., Quinn, C. E., McClenaghan, V., Patterson, C., McGivern, R. C., Harbinson, M., & McVeigh, G. E. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111411324 · Cited by 11
Boscari, F., D’Anna, M., Bonora, B. M., Tresso, S., Cappellari, R., Avogaro, A., Bruttomesso, D., & Fadini, G. P. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01278-6 · Cited by 12
Cryer, P. E. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch33 · Cited by 16
Sakai, T., Aoyama, K., Inazumi, K., Kikuchi, R., Sato, Y., Tada, A., Hirata, T., & Morimoto, J. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107962 · Cited by 10
Metadata
- Authors
- Lachin, J. M., Genuth, S., Nathan, D. M., Zinman, B., Rutledge, B. N., & for the DCCT/EDIC Research Group
- Affiliations
- George Washington University (US)
- Case Western Reserve University (US)
- Harvard University (US)
- Mount Sinai Hospital (CA)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-04-01
- Volume
- 57
- Issue
- 4
- Pages
- 995-1001
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W1992103610
- Cited by
- 555
- References
- 13
- Citations by year
- 2026: 21 · 2025: 41 · 2024: 31 · 2023: 31 · 2022: 34 · 2021: 28 · 2020: 31 · 2019: 26 · 2018: 31 · 2017: 31 · 2016: 30 · 2015: 31 · 2014: 36 · 2013: 36 · 2012: 25
- FWCI
- 22.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute
- National Eye Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- NIH Clinical Center
- Division of Diabetes, Endocrinology, and Metabolic Diseases
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- glycemic exposure, glycemic variability, postprandial hyperglycemia, microvascular complications, diabetic retinopathy progression, HbA1c, tight glycemic control, Diabetes Control and Complications Trial
- MeSH terms
- Adolescent, Adult, Diabetes Mellitus, Type 1, Diabetic Retinopathy, Female, Glycated Hemoglobin, Humans, Insulin, Male, Reproducibility of Results, Models, Statistical, Cohort Studies, Biomarkers, Disease Progression, Patient Selection, Racial Groups
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.